valganciclovir [Valcyte]
ApprovedCompleted 2 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Kidney Transplantation, Cytomegalovirus Infections
Conditions
Kidney Transplantation, Cytomegalovirus Infections
Trial Timeline
Jul 31, 2011 → May 31, 2013
NCT ID
NCT01376804About valganciclovir [Valcyte]
valganciclovir [Valcyte] is a approved stage product being developed by Roche for Kidney Transplantation, Cytomegalovirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01376804. Target conditions include Kidney Transplantation, Cytomegalovirus Infections.
What happened to similar drugs?
20 of 20 similar drugs in Kidney Transplantation, Cytomegalovirus Infections were approved
Approved (20) Terminated (1) Active (0)
✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01376804 | Approved | Completed |
| NCT01165580 | Phase 1 | Completed |
| NCT00377741 | Phase 1 | Completed |
| NCT00090766 | Phase 2/3 | Completed |
Competing Products
20 competing products in Kidney Transplantation, Cytomegalovirus Infections